Ovid Therapeutics Inc.
OVID· Nasdaq
Released Nov 10, 2021, before the open
10-Q filed Nov 10, 2021, 41 days after period end · 0000950170-21-004066
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | $6.91M | — | — |
| Net Income | -$11.38M | -$16.42M | -$16.63M | -$12.96M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.17 |
| -$0.28 |
| -$0.43 |
| -$0.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.